Zoetis Inc. (NYSE:ZTS) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,141,144 shares of the company's stock after selling 12,317 shares during the period. Hsbc Holdings PLC owned approximately 0.25% of Zoetis worth $185,842,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. raised its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the period. Murphy & Mullick Capital Management Corp acquired a new position in Zoetis during the fourth quarter valued at approximately $44,000. Asset Planning Inc purchased a new stake in Zoetis during the fourth quarter worth approximately $58,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Zoetis in the fourth quarter worth $59,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ZTS shares. Piper Sandler upped their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Stifel Nicolaus dropped their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $214.40.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 over the last quarter. 0.16% of the stock is owned by company insiders.

Zoetis Stock Performance

Shares of Zoetis stock opened at $150.17 on Wednesday. The firm has a market cap of $67.00 billion, a PE ratio of 27.45, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The firm's 50-day simple moving average is $159.19 and its 200-day simple moving average is $169.22. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.33%. Zoetis's dividend payout ratio (DPR) is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.